INTRODUCTION
============

Methamphetamine (METH) is a psychomotor stimulant with high liability for abuse, and METH abuse has become a very serious social problem in Japan \[[@R1]\]. Chronic METH abusers have been shown to have persistent dopaminergic deficits \[[@R2],[@R3]\]. Amphetamines are thought to produce their stimulant effects mainly *via* the dopaminergic system \[[@R4],[@R5]\], although other systems may also be involved. Dopamine D1 and D2 receptors form heterodimeric complexes with adenosine A1 and A2a receptors respectly, which modulate their responsiveness \[[@R6]-[@R9]\], suggesting that responses to amphetamines may also depend on adenosinergic function.

Several lines of evidence suggest that adenosine A1 receptors play a role in inhibiting the effects of METH. Adenosine receptor antagonists potentiate the effects of lower METH doses and substitute for the discriminative stimulus effects of METH \[[@R10],[@R11]\]. Adenosine receptor agonists protect against METH-induced neurotoxicity, and amphetamine-induced stereotypy and locomotor activity, and reduce the acquisition of conditioned place preference induced by amphetamine \[[@R12]-[@R15]\]. These results suggest that adenosine A1 receptors play important roles in the expression of METH-induced neurotoxicities and behaviors.

To date, however, there has been no association analysis between A1 adenosine receptor (*ADORA1*) gene variants and drug addiction. The purpose of this study was (1) to identify novel sequence variants in all coding exons as well as exonintron boundaries of the *ADORA1* gene in Japanese, and (2) to investigate whether these polymorphisms and/or haplotypes were associated with METH dependence/psychosis.

MATERIALS AND METHODS
=====================

Subjects
--------

One-hundred seventy-one unrelated patients with METH dependence/psychosis (138 males and 33 females; mean age 37.5±12.0 years) meeting ICD-10-DCR criteria (F15.2 and F15.5) were used as case subjects; they were outpatients or inpatients of psychiatric hospitals. The 229 control subjects (119 males and 110 females; mean age 41.2±12.3 years) were mostly medical staff members who had neither personal nor familial history of drug dependence or psychotic disorders, as verified by a clinical interview. All subjects were Japanese, born and living in the northern Kyushu, Setouchi, Chukyo, Tokai, and Kanto regions. This study was approved by the ethical committees of each institute of the Japanese Genetics Initiative for Drug Abuse (JGIDA), and all subjects provided written informed consent for the use of their DNA samples for this research \[[@R16]\]. After informed consent was obtained, blood samples were drawn and genomic DNA was extracted by the phenol/chloroform method.

Defining Variants of the *ADORA1* Gene
--------------------------------------

Initially, DNA samples from 16 METH dependent/psychotic patients were used to identify nucleotide variants within the *ADORA1* gene (GenBank accession no. AC105940). Exon numbers were based on the report by Ren and colleagues \[[@R17]\]. Exons 1A, 1B, 2, 3 and exon-intron boundaries were amplified by polymerase chain reaction (PCR) using a thermal cycler (Astec, Fukuoka, Japan), and the products were sequenced in both directions using BigDye terminators (Applied Biosystems, Foster City, CA) by an ABI Genetic analyzer 3100 (Applied Biosystems). The primer sequences used in this study are shown in Table **[1](#T1){ref-type="table"}**.

Genotyping of IVS1A+182 (rs56298433) was performed by PCR amplification using 2F-2R primers followed by restriction enzyme *Nla* III digestion. Genotyping of Exon2+363 (rs10920568) was performed by PCR amplification using 4F-4R primers followed by sequencing with the same primers. IVS2+35826 (rs5780149) was performed by PCR amplification using 5F-9R primers followed by sequencing with 5F and 5R primers. Genotyping of Exon3+937 (rs6427994), Exon3+987 (rs41264025), and Exon3+1064 (rs16851030) was performed by PCR amplification using 5F-9R primers followed by sequencing with 7F and 7R primers.

Patient Subgroups
-----------------

For the clinical category analysis, the patients were divided into two subgroups by three different clinical features. (A) Latency of psychosis from first METH intake: less than 3 years or more than 3 years. The course of METH psychosis varied among patients, with some patients showing psychosis sooner after the first METH intake, as previously reported \[[@R16],[@R18]\]. Because the median latency was 3 years, this time point was used as the cutoff in defining the two groups. (B) Duration of psychosis after the last METH intake: transient (\<1 month) or prolonged (≧1 month). Some patients showed continuous psychotic symptoms even after METH discontinuation, as previously reported \[[@R16],[@R18]\]. Patients with the transient type showed a reduction of psychotic symptoms within one month after the discontinuation of METH consumption and the beginning of treatment with neuroleptics. Patients with the prolonged type showed a psychotic symptoms continued for more than one month even after the discontinuation of METH consumption and the beginning of neuroleptic treatment. (C) Spontaneous relapse: present or not. It has been well documented that once METH psychosis has developed, patients in the remission phase are liable to spontaneous relapse without reconsumption of METH \[[@R16],[@R18]\].

Statistical Analysis
--------------------

The Hardy-Weinberg equilibrium of genotypic frequencies in each SNP was tested by the chi-square test. The level of statistical significance was set at α= 0.05. The allelic and genotypic frequencies of the patient and control groups were compared using the chi-square test. Haplotype frequencies were calculated by the Arlequin program available from <http://anthropologie.unige.ch/arlequin> \[[@R19]\]. Locus by locus linkage disequilibrium (LD) was evaluated by D' and r^2^, which were calculated by the haplotype frequencies using the appropriate formula in the Excel program. A global test of differentiation among samples based on haplotype frequencies was also performed by the Arlequin program.

RESULTS
=======

Analysis of the *ADORA1* Gene Variants
--------------------------------------

To identify polymorphisms in the *ADORA1* gene, exons 1A, 1B, 2, and 3, and exon-intron boundaries were analyzed using genomic DNA from Japanese METH dependent/psychotic subjects. Seven SNPs were identified (Table **[2](#T2){ref-type="table"}**). Five out of seven of these SNPs were previously reported by Deckert \[[@R20]\]. In the two SNPs, the frequencies of the minor alleles differed between our patients and those of Deckert. In the Exon2+363 (rs10920568) SNP, the G allele was present in 15.5% of our Japanese controls (Table **[3](#T3){ref-type="table"}**) and 36.9% of the German controls \[[@R20]\]. In the Exon3+1064 (rs16851030) SNP, the T allele was present in 35.8% of our Japanese controls and 1.2% of the German controls \[[@R20]\]. These differences were suggested to be related to the difference in ethnicity between the two cohorts. One SNP, Exon2+363 (rs10920568), was a synonymous mutation (Ala to Ala) (Table **[2](#T2){ref-type="table"}**). All the other SNPs were located either in the introns or an untranslated region in the exon 3. Two SNPs (Exon3+937 (rs6427994) and Exon3+1454 (rs11315020)) were in linkage disequilibrium (LD) in the sense that the genotypic patterns of the 16 samples examined were the same, representing Exon3+937 (rs6427994) for these two SNPs. IVS1A+182 (rs56298433), Exon2+363 (rs10920568), IVS2+35826 (rs5780149), Exon3+937 (rs6427994), Exon3+ 987 (rs41264025), and Exon3+1064 (rs16851030) were chosen for further analysis.

Relationship Between the *ADORA1* Gene SNPs and METH Dependence/Psychosis
-------------------------------------------------------------------------

Association analyses between these SNPs in the *ADORA1* gene and METH dependence/psychosis were performed using DNA samples from 171 METH dependent/psychotic subjects and 214 control subjects (Table **[3](#T3){ref-type="table"}**). Among them, the genotypes of five control samples and three METH samples could not be determined at IVS1A+182 (rs56298433). The genotypic frequencies in these SNPs were within the Hardy-Weinberg expectations. No significant differences of the genotypic and allelic distributions of these SNPs in these samples were observed. As the minor allele frequencies of two SNPs, IVS1A+182 (rs56298433) and Exon3+987 (rs41264025), were less than 5%, another four SNPs, Exon 2+363 (rs10920568), IVS2+35826 (rs5780149), Exon3+937 (rs6427994), and Exon3+1064 (rs16851030), were used for further analyses.

A global test of differentiation among samples based on haplotype frequencies was performed using the Arlequin program, but no significant association with METH dependence/psychosis was observed (P=0.590). Haplotype frequencies were estimated by the Arlequin program, and locus by locus LD was calculated by using the appropriate formula in the Excel program. Most of the SNPs in exon 2 and exon 3 were in LD, suggesting that the locus from exon 2 to exon 3 was in a LD block (Table **[4](#T4){ref-type="table"}**).

Subcategory analyses were conducted on the clinical parameters (latency of psychosis, prognosis of psychosis, and spontaneous relapse) (Table **[5](#T5){ref-type="table"}**). Significant differences were observed in the shorter latency of psychosis (P=0.025) at Exon3+937 (rs6427994). However, this significance disappeared after Bonferroni correction by the sub-group numbers, two (P \< 0.025).

DISCUSSION
==========

We analyzed the *ADORA1* gene variations in a Japanese population and found seven SNPs in exons and exon-intron boundaries. However, no significant associations were observed between these SNPs and METH dependence/psychosis in the genotypic, allelic, haplotypic or clinically subcategorized analyses.

This is the first association analysis between *ADORA1* gene variants and drug addiction. We failed to find associations between the *ADORA1* gene SNPs and METH dependence/psychosis. While the significant difference (P=0.025) in the shorter latency of psychosis at Exon3+937 (rs6427994) disappeared after Bonferroni correction, this may have been due to the sample size, and thus further analysis with a larger sample is warranted.

The variants we found were one synonymous SNP, two intron SNPs and four exon SNPs in the untranslated region. These SNPs are unlikely to affect receptor function because they are not non-synonymous SNPs or promoter SNPs. Because several animal studies have suggested a modulatory role of adenosine receptors for dopamine systems, it remains possible that another region in the *ADORA1* gene, such as a promoter region or intron regions, contributes to the alteration of *ADORA1* gene function.

Although a few association analyses of the *ADORA1* gene and psychiatric diseases have been performed, no significant association has been reported between *ADORA1* variants and bipolar affective disorder or panic disorder \[[@R20],[@R21]\]. As caffeine is a nonselective adenosine receptor antagonist, the association between the psychoactive effects of caffeine and gene variants of adenosine receptors have also been studied. However, the anxiogenic response to an acute dose of caffeine in healthy, infrequent caffeine users was not associated with *ADORA1* gene polymorphism \[[@R22]\]. Interindividual variation in the anxiety response to amphetamine has also been studied in healthy volunteers, but no association was observed with *ADORA1* gene variants \[[@R23]\]. These results suggest that the *ADORA1* gene variations have little effect on psychiatric symptoms and/or personality traits.

In conclusion, our data suggest that the *ADORA1* gene variants may not play a major role in the development of METH dependence/psychosis.
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###### 

Primers Used in this Study

  Exon     Forward   Reverse                                 
  -------- --------- --------------------------------- ----- ---------------------------------
  Exon1A   1F:       TGG ACT GGA TGC CTT ATG GCT TAG   1R:   GGC GCA GGA GCT GAG TGA CAA TCG
           2F:       TCT CAC CCA GTA TCA CTT CCT TTG   2R:   ATC ACA TGG TAC GGC AGA GAC TCA
  Exon1B   3F:       AAT AGG GAG AAA CGC CCC AGC CTT   3R:   AAG CAC CTG TGT GGT CAG GGA AGC
  Exon2    4F:       GGT AGG AGC TGC ATG TGA CAA GTG   4R:   GCA GAG TGA GGA CTG GAG CAC GAT
  Exon3    5F:       GGC TGT CAT GAA GCA ATG ATG AGA   5R:   CCA GCG ACT TGG CGA TCT TCA GCT
           6F:       TCT ACC TGG AGG TCT TCT ACC TAA   6R:   CCC TGA AGC TCT GGA CTG CTC ATG
           7F:       GTG GTC CCT CCA CTA GGA GTT AAC   7R:   ACA GGT AAT TAC ACT CCA AGG CTC
           8F:       CTG ATA TTT GCT GGA GTG CTG GCT   8R:   ACA CCT GCA ACA GAG CTT CCA AAG
           9F:       CCT TGC TGT CAT GTG AAT CCC TCA   9R:   CAA GAG GAA GAT GCC AAT GGG AGA

###### 

*ADORA1* Gene Variants Found in the Japanese Population

  Location     Variants   rs\#         SNP Name   Function
  ------------ ---------- ------------ ---------- ------------------------
  IVS1A+182    G/T        rs56298433              intron
  Exon2+363    T/G        rs10920568   805T/G     synonymous (Ala-\>Ala)
  IVS2+35826   T4/T5      rs5780149               intron
  Exon3+937    A/C        rs6427994    1777C/A    untranslated
  Exon3+987    C/T        rs41264025   =1827C/T   untranslated
  Exon3+1064   C/T        rs16851030   1904C/T    untranslated
  Exon3+1454   T/del      rs11315020   2294insT   untranslated

The nucleotide sequence of the *ADORA1* gene was referenecd to the NCBI nucleotide database under accession number AC105940. Exon numbers were based on the report by Ren and colleagues \[[@R17]\]. The column labelled rs\# shows SNP numbers from the NCBI SNP database. The data in the column labelled SNP name are from the report by Deckert \[[@R20]\].

###### 

Genotypic and Allelic Distribution of the *ADORA1* Gene SNPs in the METH Subjects and the Controls

  SNP                       Group   N             Genotype (%)   P             Allele (%)    P                                   
  ------------------------- ------- ------------- -------------- ------------- ------------- ------------- ------------- ------- --
  IVS1A+182 (rs56298433)                          G              G/T           T                           G             T       
  Control                   224     222 (99.1%)   2 (0.9%)       0 (0.0%)      0.961         446 (99.6%)   2 (0.4%)      0.823   
                            METH    168           166 (98.8%)    2 (1.2%)      0 (0.0%)      334 (99.4%)   2 (0.6%)              
  Exon2+363 (rs10920568)                          T              T/G           G                           T             G       
  Control                   229     162 (70.7%)   63 (27.5%)     4 (1.7%)      0.333         387 (84.5%)   71 (15.5%)    0.233   
                            METH    171           132 (77.2%)    36 (21.1%)    3 (1.8%)      300 (87.7%)   42 (12.3%)            
  IVS2+35826 (rs5780149)                          T4             T4/T5         T5                          T4            T5      
  Control                   229     150 (65.5%)   69 (30.1%)     10 (4.4%)     0.887         369 (80.6%)   89 (19.4%)    0.708   
                            METH    171           108 (63.2%)    55 (32.2%)    8 (4.7%)      271 (79.2%)   71 (20.8%)            
  Exon3+937 (rs6427994)                           A              A/C           C                           A             C       
  Control                   229     2 (0.9%)      46 (20.1%)     181 (79.0%)   0.248         50 (10.9%)    408 (89.1%)   0.222   
                            METH    171           5 (2.9%)       38 (22.2%)    128 (74.9%)   48 (14.0%)    294 (86.0%)           
  Exon3+987 (rs41264025)                          C              C/T           T                           C             T       
  Control                   229     215 (93.9%)   14 (6.1%)      0 (0.0%)      0.937         444 (96.9%)   14 (3.1%)     0.888   
                            METH    171           162 (94.7%)    9 (5.3%)      0 (0.0%)      333 (97.4%)   9 (2.6%)              
  Exon3+1064 (rs16851030)                         C              C/T           T                           C             T       
  Control                   229     89 (38.9%)    116 (50.7%)    24 (10.5%)    0.071         294 (64.2%)   164 (35.8%)   0.572   
                            METH    171           80 (46.8%)     67 (39.2%)    24 (14.0%)    227 (66.4%)   115 (33.6%)           

N: number of samples.

P: Significance values between the METH subjects and the controls.

###### 

Linkage Disequilibrium Mapping of the *ADORA1* Gene

![](CN-9-137_T4)

D\' and r^2^ values for Controls are shown in the upper right and lower left, respectively.

###### 

Genotypic Distribution of the *ADORA1* Gene SNPs in Subcategorized METH Subjects

                           SNP                    Exon2+363 (rs10920568)   IVS2+35826 (rs5780149)   Exon3+937 (rs6427994)   Exon3+1064 (rs16851030)                                                                         
  ------------------------ ---------------------- ------------------------ ------------------------ ----------------------- ------------------------- ---- ----- ---- ------- --- ---- ---- ------- ---- ---- ----- ------- --
  Control                                         229                      162                      63                      4                              150   69   10          2    46   181          89   116   24      
  METH                     Latency of Psychosis                                                                                                                                                                             
  \<3 years                67                     48                       16                       3                       0.387                     46   17    4    0.684   4   10   53   0.025   30   26   11    0.173   
  ≧3 years                 71                     56                       15                       0                       0.275                     40   29    2    0.229   0   22   49   0.124   35   28   8     0.237   
  Prognosis of Psychosis                                                                                                                                                                                                    
  Transient (\<1 month)    91                     70                       19                       2                       0.465                     59   29    3    0.883   3   22   66   0.190   42   37   12    0.269   
  Prolonged (≧1 month)     56                     41                       14                       1                       0.932                     33   20    3    0.654   1   11   44   0.835   27   21   8     0.205   
  Spontaneous Relapse                                                                                                                                                                                                       
  Not present              104                    81                       22                       1                       0.381                     64   34    6    0.733   4   25   75   0.107   52   39   13    0.081   
  Present                  60                     45                       13                       2                       0.519                     39   19    2    0.923   1   11   48   0.831   25   24   11    0.163   

N: number of samples.

P: Significance values between the METH subjects and the controls.

[^1]: Current address: Research Unit of Genome New Drugs, School of Pharmacy, Nihon University, Chiba 274-8555, Japan
